Related Experiment Video
Updated: Sep 14, 2026

Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome
Published on: May 26, 2023
Mid-term outcomes after corticosteroid injection for adhesive capsulitis in patients with type-2 diabetes: a
Eve R Glenn1, Alexander R Zhu2, James H Padley2
1Department of Orthopaedics, The Johns Hopkins University School of Medicine, Baltimore, USA. eglenn8@jh.edu.
Aims:
The mid-term clinical course after intra-articular corticosteroid injection for adhesive capsulitis ("frozen shoulder") in patients with type-2 diabetes mellitus (T2DM) remains unclear. Therefore, we evaluated coded shoulder-related outcomes and selected coded complications after such injections in patients with T2DM.
Methods:
This retrospective TriNetX Research Network study identified patients with T2DM and first-time adhesive capsulitis (2004-2024). Patients receiving a coded intra-articular corticosteroid injection within 6 months after diagnosis were compared with patients without a coded injection during that period (3,820 vs. 55,234). After propensity matching, 3,819 patients remained per group. Outcomes from 6 to 12 months after diagnosis included subsequent shoulder procedures, infection, pain, stiffness, and neurologic complications (P<.05).
Results:
The injection cohort had a higher incidence of new shoulder pain within 6-12 months after diagnosis (11%) compared with the no-injection cohort (5%) (relative risk [RR] 2.4, P<.0001). The incidence of subsequent arthrocentesis, aspiration, or injection procedures was also higher in the injection cohort (12%) than in the no-injection cohort (5%) (RR 2.4, P<.0001). The injection cohort had a higher incidence of shoulder arthroscopy (2%) than the no-injection cohort (1%) (RR 2.2, P=.0001). Despite these higher intervention rates, no differences were observed in coded infection rates, persistent shoulder stiffness, or neurologic complications.
Conclusion:
In patients with T2DM and adhesive capsulitis, receipt of a coded intra-articular corticosteroid injection within 6 months after diagnosis was associated with higher incidence of subsequent shoulder procedures and persistent joint pain at mid-term follow-up. These findings may reflect confounding by indication and a more complex disease course among patients selected for injection rather than a direct adverse effect of corticosteroid therapy. Tailored treatment strategies for adhesive capsulitis in patients with T2DM should account for distinct metabolic and inflammatory factors that may influence treatment response and recovery.
Level Of Evidence:
III.
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes Mellitus: Type 2 and Gestational
Type II Diabetes II: Pathophysiology
Type I Diabetes III: Clinical Manifestations
Type I Diabetes II: Pathophysiology
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis